Evotec BioSystems AG is not about to embark on a shopping spree to fulfil its ambitions of being the pharmaceutical industry's partner of choice for drug discovery and development services, notwithstanding its acquisition of Oxford Asymmetry International plc last week. Moreover, unlike other toolkit companies, Evotec has no intentions of shifting downstream into in-house product development.

Evotec (NMarkt:EVT, Hamburg, Germany) will pay E

"By combining our biology with Oxford Asymmetry's chemicals